BMS's anti-PD1 Opdivo takes lead in lung cancer
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's lead immune-oncology product Opdivo (nivolumab) looks set to become the first PD-1 inhibitor to gain approval for a major lung cancer indication after an interim analysis of the Phase III CheckMate–017 study showed that it improved overall survival compared with the control chemotherapy arm.